CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Oct. 29, 2016	Oct. 31, 2015
Cash flows from operating activities:
Net loss	$ (108,136)	$ (107,629)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	70,497	69,012
Amortization of lease-related interests	3,022	3,207
Impairment charges	315	425
Share-based compensation expense	2,162	2,338
Loss (gain) on sale of property, fixtures and equipment	197	(2,457)
Reclassifications of accumulated other comprehensive loss	4,391	4,774
Loss on extinguishment of debt	676	4,862
Amortization of deferred financing costs and debt discount	3,200	2,227
Deferred income tax benefit	(446)	(596)
Changes in operating assets and liabilities:
Increase in merchandise inventories	(234,203)	(259,525)
Decrease in prepaid expenses and other current assets	18,241	9,399
Decrease in other long-term assets	1,684	290
Increase in accounts payable	161,402	151,915
Increase (decrease) in accrued payroll and benefits and accrued expenses	5,420	(6,976)
Decrease in other long-term liabilities	(9,394)	(12,005)
Net cash used in operating activities	(80,972)	(140,739)
Cash flows from investing activities:
Capital expenditures	(43,933)	(70,473)
Proceeds from insurance claim		1,510
Proceeds from sale of property, fixtures and equipment	8	85,268
Net cash (used in) provided by investing activities	(43,925)	16,305
Cash flows from financing activities:
Payments on long-term debt and capital lease and financing obligations	(396,347)	(485,015)
Proceeds from issuance of long-term debt and financing obligations	519,466	624,313
Cash dividends paid		(3,014)
Restricted shares forfeited in lieu of payroll taxes	(191)	(399)
Proceeds from stock options exercised		454
Deferred financing costs paid	(5,563)	(314)
Increase in book overdraft balances	7,628	1,323
Net cash provided by financing activities	124,993	137,348
Net increase in cash and cash equivalents	96	12,914
Cash and cash equivalents at beginning of period	6,879	8,753
Cash and cash equivalents at end of period	$ 6,975	$ 21,667